Lantern Pharma shares surge 15.79% after-hours as CEO highlights AI-driven drug discovery advancements.

Lantern Pharma (NASDAQ: LTRN) surged 15.79% in after-hours trading following CEO Panna Sharma’s interview with FintechTV, where she highlighted the company’s AI platform’s advancements in accelerating oncology drug development. The platform’s ability to self-learn, model molecules, predict patient responses, and identify new indications—while reducing timelines and costs—underscored its strategic value. Sharma emphasized upcoming data milestones from the LP-184 program and global commercialization plans for the AI tool, positioning Lantern to capitalize on AI-driven drug discovery. The remarks reinforced investor confidence in the company’s potential to transform oncology therapeutics through machine learning and synthetic lethality programs, aligning with the sharp post-market price rise.